Ciphergen Announces Issuance of Patent for SELDI-TOF-MS Assisted Protein Purification
May 23 2005 - 10:00AM
PR Newswire (US)
Ciphergen Announces Issuance of Patent for SELDI-TOF-MS Assisted
Protein Purification Complements Existing Patents Covering
Ciphergen's Pattern Track(TM) Biomarker Discovery to Assay Process
including Protein Identification FREMONT, Calif., May 23
/PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH)
announced today that the United States Patent and Trademark Office
has issued Ciphergen U.S. Patent 6,881,586, directed to methods of
rapidly purifying proteins. The methods involve using
ProteinChip(R) chromatographic arrays integrated with SELDI-TOF-MS
detection to rapidly identify "on-chip" conditions for purifying a
protein for applications including protein identification. "Protein
purification is a major bottleneck today in protein
identification," said William E. Rich, President and CEO of
Ciphergen. "Our Biomarker Discovery Center(R) scientists as well as
leading researchers in our customer base have successfully used
this process to purify and identify protein biomarkers discovered
and validated through our Pattern Track process." Using a range of
ProteinChip array chromatographic surfaces and wash conditions,
scientists can quickly identify those combinations that optimize
target protein purification conditions. Scientists can then
translate these on-chip conditions into a column chromatography
protocol for purifying the protein at lab scale. This method
greatly aids in providing rapid protein sequencing as well as
purification for protein-protein interaction studies,
crystallography or activity assays. About Ciphergen Ciphergen's
Biosystems Division develops, manufactures and markets a family of
ProteinChip(R) Systems and services for clinical, research, and
process proteomics applications. ProteinChip Systems enable protein
discovery, characterization, identification and assay development
to provide researchers with predictive, multi-marker assay
capabilities and a better understanding of biological function at
the protein level. Ciphergen's Diagnostics Division is dedicated to
the discovery of protein biomarkers and panels of biomarkers and
their development into protein molecular diagnostic tests that
improve patient care; and to providing collaborative R&D
services through its Biomarker Discovery Center(R) laboratories for
biomarker discovery for new diagnostic tests as well as
pharmacoproteomic services for improved drug toxicology, efficacy
and theranostic assays. Additional information about Ciphergen can
be found at http://www.ciphergen.com/. Safe Harbor Statement Note
Regarding Forward-Looking Statements: For purposes of the Private
Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
forward-looking statements include statements regarding the use of
ProteinChip arrays to rapidly purify proteins for protein
identification, interaction studies, crystallography or activity
assays as well as statements regarding the diagnostic tests that
Ciphergen Diagnostics is developing. Actual results may differ
materially from those projected in such forward-looking statements
due to various factors, including ProteinChip technology's ability
to consistently and rapidly purify proteins, ProteinChip
technology's ability to successfully discover, validate and assay
biomarkers and patterns of biomarkers that are highly predictive
and therefore meet with customer acceptance as diagnostics, and our
ability to protect and promote our proprietary technologies.
Investors should consult Ciphergen's filings with the Securities
and Exchange Commission, including its Form 10-Q dated May 10,
2005, for further information regarding these and other risks of
the Company's business. NOTE: Ciphergen, ProteinChip and Biomarker
Discovery Center are registered trademarks of Ciphergen Biosystems,
Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue
Carruthers, Investor Relations of Ciphergen Biosystems, Inc.,
+1-510-505-2233 Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024